Sign in
Taking people in United StatesNo phase

Follows pregnant women taking ozanimod and their babies' health

Observes outcomes in pregnant women with multiple sclerosis who take ozanimod.

Key facts

Who runs it
Bristol-Myers Squibb
Where
Bethesda, United StatesSee the 2 sitesAlso in 1 other country, 1 site
Trial code
Registry title
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
Status
Recruiting
People taking part
1,182 people, planned
Started
15 Jul 2022
Expected to end
30 Jun 2032
Type of study
Observational, 3 groups
Record updated
20 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women with multiple sclerosis (MS) who are pregnant now or were pregnant recently. It follows how ozanimod exposure affects mother and baby.

Sex
Women only.
Disease stage
Diagnosis of multiple sclerosis (MS).
Earlier treatment
People who took other S1P therapies, cladribine, or mitoxantrone during the first trimester cannot join.

Main reasons for not taking part

  • Exposure to other S1P therapies during the first trimester
  • Exposure to cladribine during the first trimester
  • Exposure to mitoxantrone during the first trimester
  • Not living in the United States, Canada or Germany

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Diagnosis of Multiple sclerosis (MS)
  • Currently or recently pregnant
  • Reside in the United States, Canada or Germany

Who cannot take part

  • Exposure to other S1P therapies, cladribine, or mitoxantrone during the first trimester; Other protocol-defined inclusion/exclusion criteria apply

Where in United States

Also in 1 other country, 1 site

  • EvideraBethesda, United StatesContact: Marielle Bassel, Site 0001Taking people
  • Evidera INC.Bethesda, United StatesContact: Marielle Bassel, Site 0003Taking people

About the trial

What the trial wants to find out

The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.

The 3 groups in the trial

  • Ozanimod-exposed participants

    Women with a diagnosis of multiple sclerosis (MS) who are exposed to ozanimod during the exposure window.

  • Comparator-exposed participants

    Women with a diagnosis of MS who are not exposed to ozanimod or other sphingosine 1-phosphate (S1P) therapies during the exposure window but who are exposed to other products approved to treat MS during the exposure window.

  • Unexposed participants

    Women with a diagnosis of MS who are not exposed to ozanimod or other products approved to treat MS during the exposure window.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
ZEPOSIA® (Ozanimod) Pregnancy Registry: A Prospective, Observational Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
Plain-language title
Follows pregnant women taking ozanimod and their babies' healthGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
20 November 2025